Citations

Clear

21 citation(s) found for "Lee, William".

Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants
Barrett, Kelly M. Schiabor , Hajek, Catherine, Lu, James T. , Lynch, Kate , Sturm, Amy C., Haldeman‐Englert, Chad , Stoller, Douglas , Chapman, Christopher N., Chahal, C. Anwar A. , Judge, Daniel P., Olson, Douglas A., Lee, William , Cirulli, Elizabeth T., Chahal, Choudhary Anwar A , Hajek, Catherine A. , Lynch, Kate, Senter, Leigha , Sturm, Amy C. , Stoller, Douglas A. , Judge, Daniel P. , Olson, Douglas A., Grzymski, Joseph J. , Cirulli, Elizabeth T. , Bolze, Alexandre

Mayo Clinic

JCO Oncology Advances | May 12, 2026 | Volume: 3 | Issue: 2 | Pages: No page available

10.1200/oa-25-00075 Get It

PURPOSE The Lynch syndrome (LS) genes, MLH1 , MSH2 , MSH6 , and PMS2 , are considered to be some of the highest-priority genes to be tested for population genomic screening, with the aim to prevent and detect cancers early in those with a higher risk for such diagnoses. The objective of this study was to determine the risk of cancer associated with pathogenic variants in MLH1 , MSH2 , MSH6 , or PMS2 in the general population to build evidence-based guidelines for population genomic screening METHODS This retrospective case-control study uses Helix Research Network data from 230,159 participants across nine US health systems. Variant interpretation was performed following the American College of Medical Genetics and Association for Molecular Pathology guidelines. Clinical diagnoses were identified from electronic health records and claims data for 11 cancer types associated with LS, including colorectal and endometrial cancers. RESULTS Individuals with pathogenic variants in MLH1 , MSH2 , and MSH6 showed substantial risk for LS-related cancers compared with those without pathogenic variants. Conversely, individuals with pathogenic variants in PMS2 had no increase in risk for all 11 LS-associated cancers with hazard ratio (HR) of 1.0 (95% CI, 0.6 to 1.8) compared with those without a pathogenic variant. There was a small increase in risk when restricting the analysis to colorectal cancer with an HR of 3.5 (1.7-7.4). This increase in colorectal cancer risk was predominantly observed after age 60 years, 10 years after US Preventive Services Task Force guidelines recommend starting colonoscopies for the average population. Up to age 60 years, 2.6% of individuals with PMS2 pathogenic variants were diagnosed with colorectal cancer, closer to the general population (0.7%) than those with MLH1 (37.3%), MSH2 (28.9%), or MSH6 (6.7%) pathogenic variants. For 100,000 individuals screened for PMS2 , 854 additional colonoscopies would be performed, which would prevent or detect early 3.2 colorectal cancers. CONCLUSION This analysis across nine health systems highlights the clinical phenotypes of PMS2 pathogenic germline variants in the entire population.
Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative
Paredes, Anghela Z. , Beckhorn, Catherine B , Fusco, Joseph , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Jensen, Amanda , Dasgupta, Roshni, Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M., Murphy, Andrew J., Piché, Nelson , Le‐Nguyen, Annie, Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Lopez, A. Javier, Mello, Kelsey , Short, Joshua , Petroze, Robin T. , Rajavel, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Fowler, Kathryn , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit, Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G., Barkhordar, Aaron, Austin, Mary, Coakley, Brian A. , Murphy, Joseph T., Pitonak, M., Boehmer, Chloé , Beckhorn, Catherine , Kastenberg, Zachary J , Lautz, Timothy , Brungardt, Joseph G , Murphy, Andrew J , Thompson, Grace R , Glick, Richard D , Seemann, Natashia M , Joshi, Devashish , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Polites, Stephanie F. , Stetson, Alyssa , Lee, William G , Barkhordar, Aaron , Malek, Marcus M , Rinehardt, Hannah , Tracy, Elisabeth T. , Leraas, Harold J. , Hoyt, David , Marchese, Charles R. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Talbot, Lindsay J , Davidoff, Andrew M. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , Mannava, Sindhu V , Castle, Shannon L. , Lopez, Adriana, Rajavel, Shay , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn, Brown, Erin G. , Le, Hau D. , Ahmed, Tamer, Ehrlich, Peter F. , Gorgy, Merit , Kim, Eugene S. , Kahan, Anastasia M , Murphy, Joseph T., Malek, Marcus M.

Mayo Clinic

Pediatric Blood & Cancer | March 27, 2026 | Volume: 73 | Issue: 6 | Pages: No page available

10.1002/1545-5017.70296 | PMID 41889149 Get It

ABSTRACT Purpose Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods A multicenter retrospective review was performed by institutions participating in the Pediatric Surgical Oncology Research Collaborative. Children younger than 21 years old with MRTK diagnosed between 2000 and 2022 were included. Results Sixty‐nine patients were identified with MRTK and met the inclusion criteria. Median age of diagnosis was 10.1 months. Overall survival (OS) at 1, 5, and 10 years was 49%, 32%, and 19%, respectively. Patients with local Stage III disease who underwent upfront resection ( n = 18) compared to those who had delayed resection after NAT ( n = 15) had a similar OS, median OS greater than 60 months versus 14.6 months, respectively; p = 0.396. The surgical timing groups were balanced in terms of the presence of metastasis, length of follow‐up, and tumor characteristics. There was one occurrence of primary intraoperative tumor spill and two occurrences of organ injury in the upfront resection group compared to none in the delayed resection group. Conclusion MRTK carries a poor prognosis despite multimodal treatment. Histologic diagnosis may not be confirmed at presentation, and MRTK cannot be reliably distinguished from Wilms tumor on imaging alone. As overall survival is similar, the decision regarding surgical timing in locally advanced tumors should be individualized based on perceived resectability, balancing the risk of intraoperative complications against the possibility of tumor progression during neoadjuvant therapy.
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Schermerhorn, Sophia M. V. , Vore, Emily , Bondoc, Alexander J, Ayala, Samantha, Kastenberg, Zachary J. , Arkin, Cameron, Malek, Marcus M. , Campwala, Insiyah, Aldrink, Jennifer H. , Horvath, Kyle , Piché, Nelson , Osman, Yasmin, Brown, Erin G, Doyle, Kathleen, Abril, Paige, Roach, Jonathan P, Ziogas, Ioannis A. , Rhee, Daniel S. , Chidiac, Charbel, Debertin, Julia , Craig, Brian T. , Lee, W. N., Barkhordar, Aaron, Joshi, Devashish , Stellon, Michael , Davies, Dafydd A., Boehmer, Chloé , Dasgupta, Roshni, Kastenberg, Zachary J , Arkin, Cameron , Malek, Marcus M , Aldrink, Jennifer H , Horvath, Kyle Z , Polites, Stephanie F. , Lee, William G , Barkhordar, Aaron , Joshi, Devashish , Beckhorn, Catherine , Dasgupta, Roshni , Bondoc, Alexander , Lautz, Timothy B. , Campwala, Insiyah , Brown, Erin G. , Roach, Jonathan P. , Chidiac, Charbel , Lal, Dave R. , Kim, Eugene S. , Le, Hau D. , Tracy, Elisabeth T. , Beckhorn, Catherine B , Dasgupta, Roshni

Mayo Clinic

Cancer | February 7, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70274 | PMID 41653066 Get It

ABSTRACT Background Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
Contemporary Biology, Management, and Outcomes of Renal Medullary Carcinoma in Children and Adults: A Pediatric Surgical Oncology Research Collaborative Study
Beckhorn, Catherine B , Malek, Marcus M. , Lovvorn, Harold N. , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Hoyt, David , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Marchese, Charles R. , Jensen, Amanda , Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M. , Piché, Nelson , Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Castle, Shannon L. , Mello, Kathryn Bandeira de, Short, Joshua , Petroze, Robin T. , Rajaval, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Newman, Erika A. , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit , Polites, Stephanie F. , Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G. , Barkhordar, Aaron, Austin, Mary T. , Coakley, Brian A. , Kahan, Anastasia M , Murphy, Joseph T., Pitonak, Michael, Boehmer, Chloé , Tracy, Elisabeth T. , Kastenberg, Zachary J , Hoyt, David W , Cost, Nicholas G , Marchese, Charles R , Lautz, Timothy , Lundstedt, John , Brungardt, Joseph G , Talbot, Lindsay J , Murphy, Andrew J , Aldrink, Jennifer H , Piche, Nelson , Mannava, Sindhu V , Fialkowski, Elizabeth A , Rich, Barrie S , Seemann, Natashia M , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Barkhordar, Aaron , Beckhorn, Catherine , Tracy, Elisabeth T , Malek, Marcus M , Kahan, Anastasia Morgan , Leraas, Harold J. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Murphy, Andrew J. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , López, Adriana , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn L. , Brown, Erin G. , Abril, Paige, Rinehardt, Hannah , Le, Hau D. , Ahmed, Tamer, Kim, Eugene S. , Pitonak, M.

Mayo Clinic

Pediatric Blood & Cancer | May 21, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31774 | PMID 40394815 Get It

ABSTRACTBackgroundRenal medullary carcinoma (RMC) is an aggressive tumor associated with sickle cell trait. Despite treatment advances for other rare renal tumors, RMC survival remains poor. We aimed to describe the contemporary management and survival of children and adults with RMC.ProcedureIn this multicenter retrospective cohort study, Pediatric Surgical Oncology Research Collaborative sites searched their databases for patients diagnosed with RMC (2000–2022). Descriptive statistics were calculated and survival analyses performed using Kaplan–Meier and Cox regression.ResultsThirty‐four patients with RMC were identified. Median age was 19 years (IQR: 15–28; range: 7–52). Most were male (24/34; 71%), Black (27/32; 84%), had sickle cell trait or disease (30/33; 91%), presented with metastatic disease (27/34; 79%), and were symptomatic at presentation (32/34; 94%). Median overall survival (OS) was 24 months from diagnosis (16 months for children, 28 months for adults, p = 0.6). Receipt of platinum‐based chemotherapy (23/34; 68%) was associated with significantly higher OS than other regimens (35 vs. 5 months, p < 0.001). Nephrectomy (24/34; 71%) was associated with significantly improved OS compared with non‐operative management (34 vs. 7 months, p = 0.001). Immunotherapy, targeted therapy, or radiation therapy were not associated with significant differences in OS, nor were age, sex, race, sickle cell status, SMARCB1/INI‐1, stage, nephrectomy approach, retroperitoneal lymph node dissection, gross residual disease, margins, or tumor size.ConclusionsRMC survival remains poor despite newer therapies. Nephrectomy and platinum‐based chemotherapy should be considered in locally advanced and metastatic disease. Coordinated international cooperative group studies are needed to meaningfully improve RMC survival.
Clinical and pathological spectrum of disease severity among patients with acute liver failure (ALF) undergoing deceased donor liver transplantation
Tujios, Shannan R. , Sussman, Norman , Rakela, Jorge , Ganger, Daniel , Bass, Nathan M., Reuben, Adrian , Stravitz, R. Todd, Wang, Hanlin , Peng, Lan, Yeh, Matthew M., Hatfield, Bryce , Lee, William M. , Group, for the Acute Liver Failure Study, Rakela, Jorge L, Lee, William M , Rule, Jody A. , Kleiner, David Erwin , Choi, Eun-Young Karen , Yang, Guang‐Yu , Gill, Ryan M. , Fontana, Robert J. , Group, for the Acute Liver Failure Study

Mayo Clinic

Liver Transplantation | May 9, 2025 | Volume: 31 | Issue: 11 | Pages: 1368-1378

10.1097/lvt.0000000000000634 | PMID 40341552 Get It

Listing and transplanting patients with acute liver failure (ALF) is challenging, requiring rapid assessment of the likelihood of recovery. The availability of a large number of ALF liver explants, along with their clinical data, afforded an opportunity to retrospectively evaluate liver transplantation (LT) decision-making. We hypothesized that, with the benefit of hindsight, a small number of patients might have recovered without LT. Three hundred liver explants from ALF patients of varying etiologies who had undergone LT over 22 years in the Acute Liver Failure Study Group registry were reviewed for histopathological features and degree of necrosis by a committee of 8 hepatopathologists. A second committee of 8 experienced transplant hepatologists independently reviewed clinical data on these same 300 patients and retrospectively scored the likelihood that each patient required transplantation. Only 3 (1%) of those reviewed by the Clinical Committee were considered to “Definitely” not require liver grafting, while an additional 10 (3.3%) were deemed to “Possibly” not require transplantation (Not Likely Group, N=13). There was no difference in the degree of necrosis in explants in these groups, when compared to the remaining Likely Group, N=287 (95.6%), except in acetaminophen (APAP)-associated ALF, where the degree of necrosis was more uniformly graded as severe, correlating with the need for transplantation. Virtually every patient undergoing LT for ALF retrospectively appeared to need their transplant, based on expert clinical consensus review. Overall, there was poor correlation between clinical severity and apparent degree of necrosis seen in the 300 liver explants, except perhaps for APAP subjects.
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus
Cohen, Elisabeth J. , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Warner, David B., Lu, Ying , Twi-Yeboah, Alberta , Kim, Jiyu , Lopez-Jimenez, Carlos, Laury, Sarah, Jeng, Bennie H., Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Keenan, Jeremy, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Sugar, Alan , Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Harris, David J. , Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad Fitri , Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, María José , Barron, Bruce J., Hindman, Holly B. , Wise, R., Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, Ann M, Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John E., Ingraham, Herbert J., Guibord, Nathalie M., Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., FORSTOT, S. LANCE, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Ashe, S, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, M. Christopher , Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Robert, Marie‐Claude , Rullo, Jacob, Johnson, Davin , Mah, Dean, Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly , Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Meyer, Jay J. , Niederer, Rachael L. , Colby, Kathryn , McLeod, Stephen D. , Melia, Michele , Sugar, Elizabeth A. , Taylor, Carol R., Nagel, Maria A. , Lass, Jonathan H. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Warner, David B., Lu, Ying, Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Hamrah, Pedram , Lee, Hyunjoo, Weikert, Mitchell P. , Hood, Christopher T. , Woodward, Maria A. , Shtein, Roni Mintz , Zaffos, Joshua, Prescott, Christina R. , Haberman, Ilyse D. , Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Amir, Ahmad, Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Barron, Bruce, Wise, Ronald, Shieh, Christine , Thorne, George, Renucci, A., Sivaraman, Kavitha, Affeldt, John, Guibord, Nathalie M, Lin, Amy , Patel, Ravi, Asbell, Penny A. , Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Yung, C.–W., Lin, Charles C. , Vyas, Neil M, Oates, Dale, Veena, Mathew, Goshe, Jeffrey M. , Sharma, Vikas , Miller, Darby D. , Ma, Jeffrey H, Dupps, William Joseph

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 269

10.1001/jamaophthalmol.2024.6114 | PMID 40048183 Get It

Importance High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. Objective To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). Design, Setting, and Participants The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (&amp;lt;60 years vs ≥60 years) and disease duration (&amp;lt;6 months vs ≥6 months). Interventions A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. Main Outcomes and Measures The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. Results A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). Conclusions and Relevance Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study
Warner, David, Jeng, Bennie H., Kim, Jiyu , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Meyer, Jay J. , Lu, Ying , Twi-Yeboah, Alberta , Lopez-Jimenez, Carlos, Laury, Sarah, Cohen, Elisabeth J. , Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Hood, Christopher , Sugar, Alan M., Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad, Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, M.L. , Barron, Bruce, Hindman, Holly B. , Wise, Ronald E. , Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, A., Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John, Ingraham, Herbert J., Guibord, Nathalie M, Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., Forstot, S. Lance, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Patel, Ravi , Ashe, Sanda, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, Michael A., Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Rullo, Jacob, Johnson, Davin , Mah, Dean, Benson, Matthew , Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Lin, Charles C. , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly, Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Sharma, Vikas, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Niederer, Rachael L. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Perez-Quinones, Victor L, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Edmund, Tsui, Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Keenan, Jeremy David , Hamrah, Pedram , Lee, Hyunjoo, Barbato, John D, Weikert, Mitchell P. , Hood, Christopher, Woodward, Maria A. , Sugar, Alan, Shtein, Roni Mintz , Prescott, Christina R. , Haberman, Ilyse D. , Schrack, Katie E, Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Shieh, Christine , Thorne, George, Sivaraman, Kavitha, Lin, Amy , Repine, Karen, Asbell, Penny A. , Ashe, S, Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Hassonlou, Mojgan, Yung, C.–W., Svanda, Kerri, Keppol, Stacy, Vyas, Neil M, McHam, Lisa, Veena, Mathew, Goshe, Jeffrey M. , Miller, Darby D. , Ma, Jeffrey H

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 277

10.1001/jamaophthalmol.2024.6113 | PMID 40048191 Get It

Importance Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. Objective To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO). Design, Setting, and Participants Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months. Intervention Treatment with 1000 mg/d of valacyclovir or placebo for 12 months. Main Outcomes and Measures Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication. Results Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (&amp;lt;60 years or ≥60 years) and disease duration (recent [&amp;lt;6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, −20.8% to 25.8%]; P &amp;gt;.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months ( P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, −3.39 months [95% CI, −6.73 to −0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01). Conclusions and Relevance One year of suppressive treatment with valacyclovir was associated with a lower dosage of neuropathic pain medication. Participants in the valacyclovir group, who were younger at HZO onset and had a chronic disease duration, had lower pain scores. These secondary outcomes support consideration of 1 year of suppressive treatment with valacyclovir to reduce dosage of pain medications and pain due to HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Genetic Variants of GBP4: Reduced Risks for Drug‐Induced Acute Liver Failure in Non‐Finnish European Population
Liao, Tsung-Jen , Xia, Menghang , Hayashi, Paul H. , Pan, Bohun, Aithal, Guruprasad P. , Lucena, M. Isabel , Andrade, Raúl J. , Rule, Jody A. , Lee, William M. , Rakela, Jorge , Huang, Ruili , Chen, Minjun , Pan, Bohun

Mayo Clinic

Liver International | January 27, 2025 | Volume: 45 | Issue: 2 | Pages: No page available

10.1111/liv.70011 | PMID 39868816 Get It

ABSTRACTBackground and AimsAcute liver failure (ALF) is a serious condition, typically in individuals without prior liver disease. Drug‐induced ALF (DIALF) constitutes a major portion of ALF cases. Our research aimed to identify potential genetic predispositions to DIALF.MethodsWe analysed the potential genetic variants associated with DIALF using the whole exome sequencing data from 75 cases, including 40 non‐Finnish European cases in the pilot study. Chi‐square tests were performed for case–control analysis against the 1000 genomes project as the control. A replication study of 44 DIALF cases that included 24 non‐Finnish Europeans was conducted to validate candidate variants. The association between clinical phenotype and genotypes was analysed using one‐way analysis of variance.ResultsEight variants (rs561037, rs561042, rs608339, rs655260, rs1142886, rs1142888, rs1142889 and rs1142890) in the guanylate binding protein 4 (GBP4) were significantly associated with DIALF in non‐Finnish Europeans in the pilot study and confirmed in the replication study. Rs561037 and rs561042 were highly significant with the lowest allele frequencies in both pilot and replication studies. An association was also found between these variants and milder clinical outcomes, indicated by lower peak levels of ALT, AST and higher Karnofsky performance scores.ConclusionOur study identified eight GBP4 missense variants linked to a lower risk of DIALF in the non‐Finnish European population. The GBP4 protein, activated by interferon‐gamma, plays a critical role in innate immunity. These findings suggest that GBP4 variants might influence immune and inflammatory responses in DIALF, though further studies are needed to elucidate the underlying mechanisms.
Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial
Bruno, Benjamin, Weavil, Joshua C. , Ogle, Jonathan , Chidambaram, Nachiappan, Carey, Elizabeth J. , Danford, Christopher J. , Fricker, Zachary , Galati, Joseph , Lee, William M. , Mantry, Parvez , Shetty, Kirti , DelConte, Anthony , Patel, Mahesh , Bruno, Benjamin J , Lai, Jennifer , Lai, Jennifer C. , Sanyal, Arun J.

Mayo Clinic

Hepatology | November 8, 2024 | Volume: 81 | Issue: 6 | Pages: 1764-1775

10.1097/hep.0000000000001146 | PMID 39513970 Get It

Background and Aims: Sarcopenia is highly prevalent in patients with liver cirrhosis and is associated with adverse clinical outcomes, including HE. Androgen receptor agonists, androgen receptor agonists, can address these conditions through multimodal mechanisms of action; however, their safety and efficacy in patients with cirrhosis have not been well established. Approach and Results: In this multicenter, double-blind, phase 2 trial, men with sarcopenia and cirrhosis awaiting liver transplant were randomized 1:1 to receive either oral Androgen Receptor Agonist LPCN 1148 or placebo for 24 weeks (NCT04874350). The primary end point was the change from baseline to 24 weeks in skeletal muscle index measured by a CT scan of the L3 region, analyzed with a prespecified modified intent-to-treat population. The secondary end point was the number of overt HE events. Twenty-nine participants (mean age=59 y, MELD=17) received at least 1 dose of LPCN 1148 (n=15) or placebo (n=14). Baseline characteristics were similar between groups. Primary end point analysis demonstrated an increase in L3-skeletal muscle index measured by a CT scan of the L3 region in the LPCN 1148 group (n=15) compared to placebo (n=10), with a mean group difference of 4.4 cm2/m2 (95% CI: 1.3–7.4 cm2/m2, p=0.007). Participants in LPCN 1148 experienced fewer episodes of overt HE (Common Terminology Criteria for Adverse Events grade ≥2; p=0.02) than placebo. The number and severity of treatment-emergent adverse events were similar between arms. Conclusions: LPCN 1148 treatment improved sarcopenia and reduced the number of overt HE episodes in men with cirrhosis and sarcopenia awaiting liver transplant. These findings support additional research on the efficacy of LPCN 1148 in treating sarcopenia and preventing HE recurrence.
Indeterminate etiology of acute liver failure in North America: Less common, still grave prognosis
Patel, Parita , Livingston, Sherry , Rakela, Jorge , Stravitz, R. Todd , Reuben, Adrian , Bass, Nathan M., Tujios, Shannan R. , Larson, Anne M. , Sussman, Norman , Durkalski‐Mauldin, Valerie, Lee, William M. , Ganger, Daniel , (ALFSG), the Acute Liver Failure Study Group, Patel, Parita V , Rakela, Jorge , Rule, Jody A. , (ALFSG), the Acute Liver Failure Study Group

Mayo Clinic

Clinical Transplantation | September 14, 2023 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/ctr.15128 | PMID 37705387 Get It

AbstractBackgroundThe etiology of acute liver failure (ALF) remains one of the most important factors in determining prognosis and predicting outcomes. In a significant proportion of ALF cases, however, the etiology remains unknown and is categorized as indeterminate ALF (IND‐ALF). In this study, we summarize findings from patients with IND‐ALF from 32 transplant centers across the United States, and we compare laboratory, prognostic, and outcome data for patients with IND‐ALF.MethodsBetween 1998 and 2019, 3364 adult patients with ALF or acute liver injury (ALI) from 32 liver transplant centers were enrolled in the ALFSG registry. The primary clinical outcome of interest was 21‐day transplant‐free survival (TFS).ResultsOf the 3364 patients enrolled in the ALFSG registry, 3.4 % (n = 114) were adjudicated as true indeterminate. On multivariate analysis, patients with a lower bilirubin, lower INR, lack of use of mechanical ventilation and no clinical features of coma at baseline had a higher odds ratio of transplant free survival. The number of deaths were similar between patients with true‐IND ALF versus patients with indeterminable ALF (29.8% vs. 27.2%), with almost half of the patients requiring liver transplant (42.1% vs. 45.7%).ConclusionWe illustrate the poor prognoses that true‐IND‐ALF and indeterminable ALF carry and the need for emergency liver transplantation in most cases.